NCT06554847View on ClinicalTrials.gov

Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

October 12, 2025

Study Completion Date

August 16, 2026

Conditions

Dermatitis, AtopicEczema, Atopic

Interventions

DRUG

611

subcutaneous injection

DRUG

Placebo

subcutaneous injection

DRUG

Topical corticosteroid

Topical

Trial Locations (3)

31003

Hangzhou First People's Hospital, Hangzhou

200050

Shanghai Dermatology Hospital, Shanghai

315010

The First Affiliated Hospital of Ningbo University, Ningbo

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY

NCT06554847 - Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter